瑞典Affibody
Affibody是一家瑞典生物技術公司,專注于在其獨有的專利技術平臺基礎上開發新一代生物藥品, 這些平臺是Affibody?分子和AlbumodTM。
Affibody正在開發一系列創新藥物課題,此外也提供半衰期延長技術AlbumodTM,用于對外授權。Affibody與若干公司有持續的商業關系,包括Algeta、Amylin、Swedish Orphan Biovitrum、GE和Thermo Fisher。
Affibody由瑞典皇家理工學院和卡羅琳斯卡研究所的研究人員于1998年創立,總部在瑞典斯德哥爾摩。公司大股東包括HealthCap和Investor Growth Capital。
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody? molecules and Albumod?.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod?, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.